

AMENDMENTS TO THE CLAIMS

Please amend the Claims as follows.

23. (Amended) A method of ~~transducing~~ transfecting ~~antigen-presenting~~ antigen presenting cells ~~of the skin~~, the steps comprising selecting a gene delivery complex comprising DNA and a compound selected from the group consisting of sugars, polyethylenimine, polyethylenimine derivatives, and mixtures thereof, and applying the complex to the skin or mucosa surfaces of an animal, wherein said DNA comprises a nucleic acid sequence encoding at least one immunogenic protein operatively linked to a promoter, wherein the immunogenic protein is from a lentivirus.

24. The method of Claim 23, wherein the compound is selected from the group consisting of glucose and polyethylenimine derivatives.

25. (Amended) The method of Claim 24, wherein the polyethylenimine derivative targets a ~~the mannose~~ receptor found on the surface of antigen presenting cells.

26. The method of Claim 25, wherein the derivative is mannosylated polyethylenimine.

27. (Amended) The method of Claim 26, wherein the mannosylated polyethylenimine is ~~derived from a linear PEI 22 kDa~~ a.

28. (Amended) The method of Claim 23, wherein the complex is electrostatically neutral. ~~(page 25, lines 9-32).~~

29. (Amended) The method of Claim 23, wherein the complex comprises ~~about 3:1-10:1~~ molar equivalent of either polyethylenimine or polyethylenimine derivative amine per molar equivalent of DNA phosphate ratio. ~~(page 25, lines 26-27, page 24).~~

30. The method of Claim 23, wherein the complex comprises ~~about 5:1~~ molar equivalent of polyethylenimine or polyethylenimine derivative amine per molar equivalent of DNA phosphate ratio. ~~(page 25, lines 26-27, page 24).~~

31. The method of Claim 23, wherein the gene delivery complex is formulated in a glucose solution.

32. (Amended) The method of Claim 31, wherein the glucose solution is ~~about~~ 5-10% glucose.

33. (Amended) The method of Claim 32, wherein the glucose solution is ~~about~~ 8% glucose.

34. (Cancelled)

35. (Amended) The method of Claim ~~34~~23, ~~wherein the activating step is performed by~~
further comprising one or more steps from the group consisting of receptor stimulation,
toxin activation, or tissue or cell injury.

36. (Cancelled)

37. (Amended) The method of Claim ~~36~~23, wherein the ~~reverse transcriptase dependent~~
~~virus~~ lentivirus is a human immunodeficiency virus.

38. The method of Claim 37, wherein the human immunodeficiency virus is replication-defective.

39. The method of Claim 38, wherein the human immunodeficiency virus is integration-defective.

40. The method of Claim 23, wherein the DNA is a plasmid.

41. The method of Claim 23, wherein the cells are Langerhans cells.

42. (New) The method of Claim 29, wherein the complex comprises 3:1 molar equivalent of polyethylenimine amine per molar equivalent of DNA phosphate.